Effectiveness of a Novel Multicomponent Treatment in patients with Fibromyalgia: Clinical study
Not Applicable
- Conditions
- FibromyalgiaM00-M99
- Registration Number
- RBR-7vyw8p
- Lead Sponsor
- niversidad Gabriela Mistral
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Data analysis completed
- Sex
- Female
- Target Recruitment
- Not specified
Inclusion Criteria
Women subjects whose age range from 18 to 60 years derived to the rehabilitate foundation with medical diagnosis of fibromyalgia based on the criteria of the American College of Rheumatology; subjects reporting moderate pain of at least 4/10 EVA; subjects who can read, write and follow basic instructions in Spanish; subjects that accept and sign the informed consent.
Exclusion Criteria
Women in stages of pregnancy and / or lactation; women with chronic oncological pain; women with metabolic disorder and / or uncontrolled comorbidities and who present some psychiatric or cognitive alteration that prevents them from participating in the study.
Study & Design
- Study Type
- Intervention
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Expected result 1- It is expected to find a decrease in pain intensity assessed through the numeric pain rating scale in the participants of the novel multicomponent treatment group compared to the standard treatment group.<br>;Result found 1 - At week 12, we found reductions in perceived pain intensity of 1.4 points (standard deviation 2.9) in the new multicomponent treatment and of 0.18 points (standard deviation 0.4) in care standard. Therefore, the difference between groups instead provides an estimate of the effect of the new multicomponent treatment on the Numeric pain rating scale-1.18 points (eta square=0.47, p<0.001).
- Secondary Outcome Measures
Name Time Method